Have a feature idea you'd love to see implemented?
Let us know!
DNLI Denali Therapeutics Inc
Price (delayed)
$21.32
Market cap
$3.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$3.03B
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing
Highlights
The EPS has plunged by 198% YoY but it has increased by 3.1% from the previous quarter
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ
Denali Therapeutics's gross profit has shrunk by 100% QoQ and by 100% YoY
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of DNLI
Market
Valuations
Earnings
Shares outstanding
143.92M
Market cap
$3.07B
Enterprise value
$3.03B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$427.49M
EBIT
-$427.46M
EBITDA
-$418.91M
Free cash flow
-$375.69M
Per share
Balance sheet
Liquidity
EPS
-$2.77
EPS diluted
-$2.77
Free cash flow per share
-$2.22
Book value per share
$9.21
Revenue per share
$0
TBVPS
$8.58
Total assets
$1.45B
Total liabilities
$135.52M
Debt
$52.52M
Equity
$1.32B
Working capital
$781.75M
Debt to equity
0.04
Current ratio
9.98
Quick ratio
9.61
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30%
Return on equity
-32.9%
Return on invested capital
-32.8%
Return on capital employed
-31.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNLI stock price
How has the Denali Therapeutics stock price performed over time
Intraday
1.91%
1 week
-0.79%
1 month
-13.61%
1 year
-4.61%
YTD
-0.65%
QTD
-26.81%
Financial performance
How have Denali Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$490.07M
Net income
-$427.49M
Gross margin
N/A
Net margin
N/A
DNLI's operating income has dropped by 189% year-on-year
Denali Therapeutics's gross profit has shrunk by 100% QoQ and by 100% YoY
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Growth
What is Denali Therapeutics's growth rate over time
Valuation
What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 198% YoY but it has increased by 3.1% from the previous quarter
DNLI's price to book (P/B) is 48% less than its 5-year quarterly average of 4.4 and 13% less than its last 4 quarters average of 2.6
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Denali Therapeutics business performance
The return on equity has dropped by 186% year-on-year but it has increased by 2.1% since the previous quarter
The return on invested capital has dropped by 176% year-on-year but it has increased by 3% since the previous quarter
The return on assets has increased by 2.3% since the previous quarter
Dividends
What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNLI.
Financial health
How did Denali Therapeutics financials performed over time
The current ratio has contracted by 38% YoY and by 20% from the previous quarter
The quick ratio has declined by 38% year-on-year and by 20% since the previous quarter
Denali Therapeutics's debt is 96% less than its equity
DNLI's debt to equity is down by 20% year-on-year
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.